Published in J Infect Dis on September 01, 1983
Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med (1990) 2.55
Pathogenesis of murine cytomegalovirus infection: identification of infected cells in the spleen during acute and latent infections. J Virol (1988) 1.83
Cytomegalovirus determinant of replication in salivary glands. J Virol (1992) 1.82
Replication of murine cytomegalovirus in differentiated macrophages as a determinant of viral pathogenesis. J Virol (1999) 1.42
Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J Gen Virol (2009) 1.40
Pathogenesis of acute murine cytomegalovirus infection in resistant and susceptible strains of mice. J Virol (1986) 1.11
MHC class I immune evasion in MCMV infection. Med Microbiol Immunol (2008) 1.10
Animal cytomegaloviruses. Microbiol Rev (1990) 1.02
Effective inhibition of K(b)- and D(b)-restricted antigen presentation in primary macrophages by murine cytomegalovirus. J Virol (2003) 0.95
Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. Proc Natl Acad Sci U S A (2011) 0.85
Effective inhibition in animals of viral pathogenesis by a ribozyme derived from RNase P catalytic RNA. Proc Natl Acad Sci U S A (2008) 0.82
Deciphering the role of DC subsets in MCMV infection to better understand immune protection against viral infections. Front Microbiol (2014) 0.81
Pulmonary macrophage function during experimental cytomegalovirus interstitial pneumonia. Infect Immun (1985) 0.78
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med (1995) 3.80
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med (1989) 2.77
Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis (1995) 2.65
Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother (1991) 2.40
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
Latent infection and the elusive cytomegalovirus. Rev Infect Dis (1983) 2.24
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Disseminated cytomegalovirus infection. Molecular analysis of virus and leukocyte interactions in viremia. J Clin Invest (1988) 2.05
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Association of cervical cytomegaloviruses with venereal disease. N Engl J Med (1973) 1.84
Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA (1987) 1.84
Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol (1997) 1.82
Immunosuppression reactivates and disseminates latent murine cytomegalovirus. J Gen Virol (1977) 1.79
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med (1988) 1.75
Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis (1970) 1.68
Spontaneous cytomegalovirus mononucleosis. Clinical and laboratory observations in nine cases. Ann Intern Med (1973) 1.65
High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest (1992) 1.62
Latent murine cytomegalovirus DNA in splenic stromal cells of mice. J Virol (1991) 1.55
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Overlapping roles of pocket proteins in the myocardium are unmasked by germ line deletion of p130 plus heart-specific deletion of Rb. Mol Cell Biol (2005) 1.48
Demographic and dietary determinants of constipation in the US population. Am J Public Health (1990) 1.47
Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med (1992) 1.47
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr (2000) 1.45
Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res (2001) 1.44
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis (1981) 1.43
Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS (1989) 1.43
Cytomegalovirus viremia detected by molecular hybridization and electron microscopy. Ann Intern Med (1984) 1.43
Left ventricular unloading during reperfusion does not limit myocardial infarct size. Circulation (1990) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Allescheria boydii infections in the immunosuppressed host. Am J Med (1977) 1.40
Interactions of human cytomegalovirus with leukocytes in vivo: analysis by in situ hybridization. Microb Pathog (1987) 1.39
Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses (1990) 1.39
Interstitial pneumonia and subclinical infection after intranasal inoculation of murine cytomegalovirus. Infect Immun (1978) 1.34
Spontaneous activation of latent cytomegalovirus from murine spleen explants. Role of lymphocytes and macrophages in release and replication of virus. J Clin Invest (1982) 1.30
Pathogenesis of reactivated latent murine cytomegalovirus infection. Am J Pathol (1979) 1.28
Clinical aspects of CNS cysticercosis. Arch Intern Med (1980) 1.27
An evaluation of dipstick-dot immunoassay in the detection of antibodies to HIV-1 and 2 in Zimbabwe. Trop Med Int Health (1997) 1.26
Interferon as a mediator of human lymphocyte suppression. J Exp Med (1980) 1.25
Biphasic viremia and viral gene expression in leukocytes during acute cytomegalovirus infection of mice. J Virol (1994) 1.24
Risk factors for HIV infection at enrollment in an urban male factory cohort in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.23
Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.22
Effect of prenatal iron deficiency on myelination in rat pups. Am J Pathol (1986) 1.21
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med (1994) 1.21
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (1999) 1.18
Detection of latent cytomegalovirus DNA in diverse organs of mice. J Infect Dis (1993) 1.15
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr (2000) 1.15
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis (1993) 1.14
Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. J Acquir Immune Defic Syndr (1993) 1.14
Activation of latent murine cytomegalovirus in vivo and in vitro: a pathogenetic role for acute infection. J Infect Dis (1982) 1.11
Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J Infect Dis (1996) 1.11
Clinical pharmacology of pivampicillin as compared with ampicillin. Antimicrob Agents Chemother (Bethesda) (1970) 1.11
Pulmonary function tests in HIV-infected patients without AIDS. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med (1995) 1.10
Virulence characteristics of murine cytomegalovirus in cell and organ cultures. Infect Immun (1983) 1.09
Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection system. J Virol Methods (1995) 1.07
Bordetella bronchiseptica bacteremia. West J Med (1984) 1.06
Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr (2001) 1.05
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 1.04
Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis (1995) 1.04
Potentiation of ethanol-induced pancreatic injury by dietary fat. Induction of chronic pancreatitis by alcohol in rats. Am J Pathol (1988) 1.03
Reactivation of latent Herpes simplex virus after pneumococcal pneumonia in mice. Infect Immun (1975) 1.02
Correlation of morphologic diagnosis of Pneumocystis carinii with the presence of pneumocystis DNA amplified by the polymerase chain reaction. Mod Pathol (1992) 1.02
Adverse effects of cytomegalovirus vaccination in mice. J Clin Invest (1980) 1.02
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr (2001) 1.02
Diagnosis of viral pneumonia. Semin Respir Infect (1988) 1.01
In vitro model of attachment of Giardia intestinalis trophozoites to IEC-6 cells, an intestinal cell line. Antimicrob Agents Chemother (1991) 1.01
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J Acquir Immune Defic Syndr (1992) 1.00
The clinical investigation of lymphadenopathy in primary care practice. JAMA (1978) 0.99
Cardioprotection by Cu,Zn-superoxide dismutase is lost at high doses in the reoxygenated heart. Free Radic Biol Med (1990) 0.99
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients. Clin Infect Dis (2001) 0.99
Reactivation of Toxoplasma gondii by cytomegalovirus disease in mice: antimicrobial activities of macrophages. J Infect Dis (1989) 0.98
Syphilis serology and HIV infection in Harare, Zimbabwe. Sex Transm Infect (1999) 0.98
Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrob Agents Chemother (1985) 0.97
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. J Virol Methods (1993) 0.97
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 0.96
HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (2000) 0.96
Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients. Antimicrob Agents Chemother (1997) 0.96
Cytomegalovirus replication in murine microglial cell cultures: suppression of permissive infection by interferon-gamma. J Infect Dis (1994) 0.96
Sexual behavior and risk factors for HIV infection in a group of male factory workers who donated blood in Harare, Zimbabwe. J Acquir Immune Defic Syndr (1992) 0.95
Propagation and titration of murine cytomegalovirus in a continuous bone marrow-derived stromal cell line (M2-10B4). J Virol Methods (1997) 0.95
Development of a Crohn's index for survey research. J Clin Epidemiol (1988) 0.95
Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses (2000) 0.92
Hypertension in beta-adducin-deficient mice. Hypertension (2000) 0.92
HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.91